Becas FERO en Cáncer de Mama (Beca FERO-GHD / Beca FERO-MANGO editions)
Who can apply: Investigadores con proyectos de investigación traslacional en cáncer de mama.
Fundació Privada d'Estudis i Recerca Oncològica (FERO) is a Spain-based cancer research funder focused on translational oncology, especially projects that move molecular discoveries into patient care. It stands out for backing young investigators, consolidating emerging research groups, and supporting highly targeted disease areas such as pediatric cancer, prostate cancer, and precision medicine through both competitive fellowships and invite-only institutional partnerships.
FERO gives a mix of open competitive fellowships and invite-only institutional partnerships, typically in Spain. Support is often substantial for a nontraditional funder, with fellowships around $100,000 and larger group-consolidation grants around $300,000, alongside longer-term program funding for selected research centers.
Applicants should target translational, clinically relevant oncology projects with a clear path to patient impact, especially if they are early-career researchers or young medical oncologists. Monitor the FERO/ASEICA call calendar closely, as at least one program opens in March and closes in April, while several major awards and institutional programs are invite-only and likely require prior relationships or institutional alignment in Spain.
Sign up free to see how well your nonprofit fits this funder, get an AI-generated pitch, and unlock similar foundations.
Current and upcoming funding from Fundació Privada d'Estudis i Recerca Oncològica that your nonprofit may be able to apply for.
Who can apply: Investigadores con proyectos de investigación traslacional en cáncer de mama.
Track these deadlines, get reminders, and see how well your nonprofit fits — free with a Kindora account.
Create a free accountDeadlines and eligibility are summarized from public sources and may change — always confirm the details on the funder's official application page before applying.